Page last updated: 2024-11-12

silvestrol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

silvestrol: isolated from the fruit and twig of Aglaia silvestris [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AglaiagenusA plant genus of the family MELIACEAE. Members contain lariciresinol, pregnanes, insecticidal rocaglamide derivatives and other compounds.[MeSH]MeliaceaeThe mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]
Aglaia silvestrisspecies[no description available]MeliaceaeThe mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID11787114
CHEMBL ID555196
CHEBI ID66484
SCHEMBL ID732092
MeSH IDM0472562

Synonyms (23)

Synonym
697235-38-4
HY-13251
bdbm50335583
silvestrol
CHEMBL555196 ,
(-)-silvestrol
chebi:66484 ,
methyl (1r,2r,3s,3ar,8bs)-6-({(2s,3r,6r)-6-[(1r)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl}oxy)-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1h-benzo[b]cyclopenta[d]furan-2-carboxylate
CS-0543
SCHEMBL732092
AKOS027326751
methyl (1r,2r,3s,3ar,8bs)-6-[[(2s,3r,6r)-6-[(1r)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran-2-carboxylate
Q27135085
MS-30982
NCGC00379005-02
nsc783538
nsc-783538
mfcd22417097
kk3y3kn5bv ,
unii-kk3y3kn5bv
silvestrol [who-dd]
1h-cyclopenta(b)benzofuran-2-carboxylic acid, 6-(((2s,3r,6r)-6-((1r)-1,2-dihydroxyethyl)-3-methoxy-1,4-dioxan-2-yl)oxy)-2,3,3a,8b-tetrahydro-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-, methyl ester, (1r,2r,3s,3ar,8bs)-
DTXSID601028120

Research Excerpts

Overview

Silvestrol is a cyclopenta[b]benzofuran that was isolated from the fruits and twigs of Aglaia foveolata, a plant indigenous to Borneo in Southeast Asia.

ExcerptReferenceRelevance
"Silvestrol is a cyclopenta[b]benzofuran that was isolated from the fruits and twigs of Aglaia foveolata, a plant indigenous to Borneo in Southeast Asia. "( Silvestrol induces early autophagy and apoptosis in human melanoma cells.
Burdette, JE; Chen, WL; Kinghorn, AD; Pan, L; Swanson, SM, 2016
)
3.32

Effects

ExcerptReferenceRelevance
"Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated."( Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
Ali, J; Bahadoor, A; Belani, J; Castro, AC; Conley, J; Douglas, M; Fritz, C; Helble, J; Lescarbeau, A; Liu, T; McGovern, K; Nair, SJ; O'Hearn, P; Palombella, VJ; Peluso, S; Slocum, K; Smith, S; Tillotson, B; Tremblay, MR; West, K; Wylie, A, 2012
)
1.5

Treatment

Silvestrol treatment in vivo did not alter liver structure. In silvestrol-treated cells, DAPI staining of nuclear chromatin displayed nucleosomal fragments.

ExcerptReferenceRelevance
"Silvestrol treatment in vivo did not alter liver structure."( Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
Bolon, B; Grever, MR; Kinghorn, AD; Kogure, T; Lucas, DM; Patel, T; Yan, I, 2013
)
1.36
"In silvestrol-treated cells, DAPI staining of nuclear chromatin displayed nucleosomal fragments."( Silvestrol induces early autophagy and apoptosis in human melanoma cells.
Burdette, JE; Chen, WL; Kinghorn, AD; Pan, L; Swanson, SM, 2016
)
2.39

Pharmacokinetics

ExcerptReferenceRelevance
" Together, these data suggest an overall favorable pharmacokinetic profile of silvestrol in mice and provide crucial information for its continued development toward potential clinical testing."( Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.
Chan, KK; Chiu, M; Covey, JM; Grever, MR; Gupta, SV; Kinghorn, AD; Ling, Y; Liu, Z; Lucas, DM; Marcucci, G; Newman, DJ; Phelps, MA; Saradhi, UV; Wang, J, 2011
)
0.92

Compound-Compound Interactions

ExcerptReferenceRelevance
"We have previously shown that inhibition of translation initiation, using the small molecule inhibitor silvestrol, induces apoptosis in a pre-clinical murine lymphoma model when combined with daunorubicin."( Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
Carrier, M; Cencic, R; Minden, M; Pelletier, J; Porco, JA; Trnkus, A, 2010
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
dioxanes
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription factor p65Homo sapiens (human)IC50 (µMol)20.00000.00011.89818.8000AID566360
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Eukaryotic initiation factor 4A-IHomo sapiens (human)EC50 (µMol)0.00390.00080.02700.0900AID704239; AID704240
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (81)

Processvia Protein(s)Taxonomy
cytoplasmic translational initiationEukaryotic initiation factor 4A-IHomo sapiens (human)
translational initiationEukaryotic initiation factor 4A-IHomo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
RNA cap bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
RNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
RNA helicase activityEukaryotic initiation factor 4A-IHomo sapiens (human)
double-stranded RNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
mRNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
translation initiation factor activityEukaryotic initiation factor 4A-IHomo sapiens (human)
helicase activityEukaryotic initiation factor 4A-IHomo sapiens (human)
protein bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
ATP bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
translation factor activity, RNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
ATP hydrolysis activityEukaryotic initiation factor 4A-IHomo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusEukaryotic initiation factor 4A-IHomo sapiens (human)
cytoplasmEukaryotic initiation factor 4A-IHomo sapiens (human)
cytosolEukaryotic initiation factor 4A-IHomo sapiens (human)
membraneEukaryotic initiation factor 4A-IHomo sapiens (human)
eukaryotic translation initiation factor 4F complexEukaryotic initiation factor 4A-IHomo sapiens (human)
extracellular exosomeEukaryotic initiation factor 4A-IHomo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay IDTitleYearJournalArticle
AID422140Growth inhibition of human Lu1 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID704208Toxicity in human RPMI18226 cells xenografted in NOD/SCID mouse assessed as incidence of dose limiting toxicity events at 0.2 mg/kg, ip qd for 5 days for 3 weeks2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704217Toxicity in human RPMI8226 cells xenografted NOD/SCID mouse assessed as compound tolerability at 1 mg/kg, ip qd for 5 days2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID424554Growth inhibition of human MCF7 cells xenografted in NCr nu/nu mouse at 0.625 to 5 mg/kg, sc once daily administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID704228Cytotoxic activity against human L3.6p1 cells incubated for 4 to 24 hrs by CellTiter-Glo luminescent cell viability assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704219Toxicity in human L3.6p1 cells xenografted BALB/c mouse assessed as compound tolerability at 1 mg/kg, ip qd for 5 days for 2 weeks2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704224Cytotoxic activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by 7-AAD dye exclusion assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID684643Anticancer activity in patient with chronic lymphocytic leukemia2012Journal of natural products, Aug-24, Volume: 75, Issue:8
Total synthesis of 2''',5'''-diepisilvestrol and its C1''' epimer: key structure activity relationships at C1''' and C2'''.
AID1478400Cytotoxicity against human Kasumi-1 cells incubated for 48 hrs by MTS assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity.
AID422137Growth inhibition of human MCF7 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID704237Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by MTS assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704209Reduction in c-myc protein level in human RPMI18226 cells xenografted in NOD/SCID mouse at 0.2 mg/kg, ip qd for 5 days for 3 weeks2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID663969Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 2.5 mg/kg, ip dosed daily for 5 days2011Journal of natural products, Jun-24, Volume: 74, Issue:6
The relevance of higher plants in lead compound discovery programs.
AID424557Acute toxicity in ip dosed mouse2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID704234Half life in mouse liver microsomes at 500 nM by LC-MS/MS method2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704230Efflux ratio of permeability from apical to basolateral over basolateral to apical side in human Caco2 cells2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704220Effect on beta-actin protein expression in human RPMI18226 cells at 100 nM by Western blotting2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID1478399Cytotoxicity against human MV4-11 cells incubated for 48 hrs by MTS assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity.
AID704239Inhibition of eIF4FA in human MDA-MB-231 cells transfected with tubulin 5'-UTR-luciferase construct assessed as reduction in translation initiation incubated for 24 hrs by differential translation assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID424552Growth inhibition of human LNCAP cells xenografted in NCr nu/nu mouse at 0.625 to 5 mg/kg, sc once daily administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID704215Drug level in tumor of human L3.6p1 cells xenografted BALB/c mouse assessed as compound tolerability at 1 mg/kg, ip measured 6 hrs post dose2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID424553Growth inhibition of human MCF7 cells xenografted in NCr nu/nu mouse at 0.625 to 5 mg/kg, ip once daily administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID704211Reduction in c-myc protein level in human L3.6p1 cells xenografted BALB/c mouse tumor at 1 mg/kg, ip measured 24 hrs post dose2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID606022Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.
AID671541Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 72 hr by scintillation counting2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
AID663975Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 2 mg/kg, ip dosed twice daily for 5 days2011Journal of natural products, Jun-24, Volume: 74, Issue:6
The relevance of higher plants in lead compound discovery programs.
AID704240Inhibition of eIF4FA in human MDA-MB-231 cells transfected with c-myc- 5'-UTR-luciferase construct assessed as reduction in translation initiation incubated for 24 hrs by differential translation assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID606024Cytotoxicity against human SF268 cells after 72 hrs by MTS assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.
AID424549Growth inhibition of human Lu1 cells xenografted in NCr nu/nu mouse at 0.625 to 5 mg/kg, ip once daily administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID671545Inhibition of recombinant eIF4A1 assessed as eIF4A1/[32P]mRNA complex formation after 10 mins by scintillation counting2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
AID704218Toxicity in human L3.6p1 cells xenografted BALB/c mouse assessed as compound tolerability at 2.5 mg/kg, ip dosed twice weekly for 2 weeks2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID606023Cytotoxicity against human H460 cells after 72 hrs by MTS assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.
AID704222Effect on beta-actin protein expression in human L3.6p1 cells at 100 nM by Western blotting2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID671544Inhibition of recombinant eIF4A1 assessed as eIF4A1/[32P]mRNA complex formation at 1 to 10 uM after 10 mins by scintillation counting in presence of hippuristanol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
AID704235Half life in human plasma at 1000 nM by mass spectrometry2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID671540Cytotoxicity against human BJAB cells after 72 hrs by PI-staining based flow cytometric analysis2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
AID684644Cytotoxicity against human breast cancer cells2012Journal of natural products, Aug-24, Volume: 75, Issue:8
Total synthesis of 2''',5'''-diepisilvestrol and its C1''' epimer: key structure activity relationships at C1''' and C2'''.
AID704223Inhibition of c-myc protein expression in human L3.6p1 cells at 100 nM by Western blotting2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704216Antitumor activity in human L3.6p1 cells xenografted in BALB/c mouse assessed as reduction in tumor growth at 1 mg/kg, ip qd for 5 days for 2 weeks2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID684645Cytotoxicity against human lung cancer cells2012Journal of natural products, Aug-24, Volume: 75, Issue:8
Total synthesis of 2''',5'''-diepisilvestrol and its C1''' epimer: key structure activity relationships at C1''' and C2'''.
AID671539Potentiation of doxorubicin antitumor activity against mouse Eu-myc/myr-AKT lymphoma cells xenografted in C57Bl/6 mouse assessed as tumor-free survival at 0.2 mg/kg, ip administered daily for 5 days2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
AID704229AUClast in iv dosed CD1 mouse2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704227Cytotoxic activity against human RPMI18226 cells incubated for 4 to 24 hrs by CellTiter-Glo luminescent cell viability assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID566359Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay2010Journal of natural products, Nov-29, Volume: 73, Issue:11
Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata.
AID424550Growth inhibition of human Lu1 cells xenografted in NCr nu/nu mouse at 0.625 to 5 mg/kg, sc once daily administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID424551Growth inhibition of human LNCAP cells xenografted in NCr nu/nu mouse at 0.625 to 5 mg/kg, ip once daily administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID704225Cytotoxic activity against human RPMI18226 cells assessed as reduction in cell viability incubated for 72 hrs by 7-AAD dye exclusion assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704214Antitumor activity in human L3.6p1 cells xenografted in BALB/c mouse assessed as reduction in tumor growth at 2.5 mg/kg, ip dosed twice weekly for 2 weeks2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID663971Oral bioavailability in C57BL/6 mouse2011Journal of natural products, Jun-24, Volume: 74, Issue:6
The relevance of higher plants in lead compound discovery programs.
AID671542Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 1 hr by scintillation counting2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
AID704213Drug level in tumor of human L3.6p1 cells xenografted BALB/c mouse assessed as compound tolerability at 1 mg/kg, ip measured 24 hrs post dose2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704236Half life in mouse plasma at 1000 nM by mass spectrometry2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704210Antitumor activity in human RPMI18226 cells xenografted in NOD/SCID mouse assessed as reduction in tumor growth at 0.2 mg/kg, ip qd for 5 days for 3 weeks2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID671543Inhibition of recombinant eIF4A1 assessed as depletion of eIF4A1/2 from eIF4F complex at 1 to 10 uM after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
AID704221Inhibition of c-myc protein expression in human RPMI18226 cells at 100 nM by Western blotting2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704212Reduction in c-myc protein level in human L3.6p1 cells xenografted BALB/c mouse tumor at 1 mg/kg, ip measured 6 hrs post dose2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID422138Growth inhibition of human LNCAP cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.
AID606021Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.
AID704238Selectivity index, ratio of EC50 for eIF4FA in human MDA-MB-231 cells transfected with tubulin 5'-UTR-luciferase construct to EC50 for eIF4FA in human MDA-MB-231 cells transfected with c-myc- 5'-UTR-luciferase construct by differential translation assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID430919Inhibition of cap-dependent translocation of firefly luciferase in mouse Krebs2 cell extract2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
AID704233Permeability from apical to basolateral side in human Caco2 cells2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID663970Systemic availability in ip dosed C57BL/6 mouse2011Journal of natural products, Jun-24, Volume: 74, Issue:6
The relevance of higher plants in lead compound discovery programs.
AID704232Half life in human liver microsomes at 500 nM by LC-MS/MS method2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID566360Inhibition of NF-kappaB p65 isolated from nuclear extract of human HeLa cells assessed as blockade of binding to biotinylated consesus sequence by chemiluminescence assay2010Journal of natural products, Nov-29, Volume: 73, Issue:11
Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata.
AID704231Half life in iv dosed CD1 mouse2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID704226Cytotoxic activity against human L3.6p1 cells assessed as reduction in cell viability incubated for 72 hrs by 7-AAD dye exclusion assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID606025Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTS assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (14.08)29.6817
2010's48 (67.61)24.3611
2020's13 (18.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.92 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index49.55 (26.88)
Search Engine Supply Index2.07 (0.95)

This Compound (35.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (12.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other64 (87.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]